There have been no major advances for the treatment of metastatic urothelial bladder cancer
(UBC) in the last 30 years. Chemotherapy is still the standard of care. Patient outcomes, …

Background Outcomes are poor for patients with previously treated, advanced or metastatic
non-small-cell lung cancer (NSCLC). The anti-programmed death ligand 1 (PD-L1) antibody …

Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with
metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based …

BACKGROUND Because a role for nuclear factor‐κB (NF‐κB) has been implicated in the
pathogenesis of pancreatic carcinoma, this transcription factor is a potential target for the …

Importance Atezolizumab (anti–programmed cell death ligand 1 [PD-L1]) is well tolerated
and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple-…

Purpose Metastatic pancreatic ductal adenocarcinoma is characterized by excessive
hyaluronan (HA) accumulation in the tumor microenvironment, elevating interstitial pressure and …

Background Next-generation sequencing has identified actionable genetic aberrations in
intrahepatic cholangiocarcinomas (iCCA), including the fibroblast growth factor receptor 2 (…

Introduction: TNBC is a mutationally complex breast cancer subtype with poor prognosis and
no current targeted therapy options. Compared with other intrinsic breast cancer subtypes, …

Erdheim-Chester disease is a rare non-Langerhans histiocytosis with multisystem
involvement. To date, there is no standard treatment for this disorder, and more than half of the …

Background: Metastatic triple-negative breast cancer (TNBC) is associated with a poor
prognosis and has no targeted therapy options. Programmed death-ligand 1 (PD-L1) expression …